Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study

Table 4 Inferential analysis RULM

	Value	SE	DF	t-value	p-value
(Intercept)	3.427	0.776	849	4.416	0.00
Baseline_m14 versus m14_m26	1.122	0.235	849	4.777	< 0.001
Baseline_m14 versus m26_m38	1.509	0.364	849	4.146	< 0.001
Age at symptom onset	0.033	0.027	169	1.235	0.22
Baseline Score	− 0.146	0.033	169	− 4.431	< 0.001
SMN2 copy number	0.465	0.621	169	0.749	0.46
Age at start of treatment	− 0.004	0.005	169	− 0.742	0.46
Gender m	0.396	0.456	169	0.869	0.39
Loss of sitting before start of treatment	− 1.533	0.664	169	− 2.308	0.02
Loss of walking before start of treatment	0.805	0.733	169	1.099	0.27

Inferential analysis evaluates the effect of age at diagnosis, age at start of treatment, SMN2 copy number (≤ 3 SMN2 copies vs. ≥ 4 SMN2 copies), gender, baseline RULM score, and past time from baseline on changes in RULM score.

ISSN: 1750-1172